Published in
Wiley, British Journal of Haematology, 3(177), p. 441-448, 2017
DOI: 10.1111/bjh.14562
Links
Tools
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Journal article published in 2017 by
Hang Quach,
Liam Fernyhough,
Ross Henderson,
Gillian Corbett,
Bart Baker,
Peter Browett,
Hilary Blacklock,
Cecily Forsyth,
Craig Underhill 
,
Paul Cannell,
Judith Trotman ,
Annette Neylon,
Simon Harrison,
Emma Link,
Arlene Swern
and other authors.
,
Paul Cannell,
Judith Trotman ,
Annette Neylon,
Simon Harrison,
Emma Link,
Arlene Swern
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 